Panic Disorder and Psychedelic-Assisted Therapy in Canada

Panic disorder affects roughly 2–3% of Canadians in any given year, with lifetime prevalence closer to 5%. It is characterized by recurrent unexpected panic attacks alongside persistent worry about future attacks or maladaptive behavioural changes — often the avoidance pattern that progresses to agoraphobia. This article is a Canadian evidence-and-pathway guide for patients with panic disorder who are evaluating psychedelic-assisted therapy. The honest framing matters here: first-line treatments — panic-specific CBT and SSRIs — are well-supported and should generally be tried first. The published psychedelic-assisted therapy evidence base for panic disorder as a primary indication is thin compared to treatment-resistant depression (TRD) or PTSD, and panic patients require particularly careful screening and substantial preparation because the dosing experience itself can resemble or trigger panic features.

Key takeaways

• Panic disorder is a DSM-5 anxiety disorder: recurrent unexpected panic attacks plus ≥1 month of persistent worry about future attacks or maladaptive behaviour change.
• Highly comorbid with agoraphobia, major depressive disorder, other anxiety disorders, and substance use.
• First-line treatments are foundational: panic-specific cognitive behavioural therapy (Craske/Barlow protocols) and SSRIs (sertraline, paroxetine, fluoxetine, escitalopram); SNRIs (venlafaxine) are also first-line per CANMAT 2018.
• Benzodiazepines are appropriate for short-term symptom control — not as monotherapy long-term given dependence and tolerance concerns.
• For treatment-resistant panic: SSRI/SNRI augmentation, switching, MAOIs (specialist), or deep TMS — psychedelic-assisted therapy is not an established next step.
• Psychedelic-assisted therapy evidence in panic disorder specifically is thin. Most psilocybin and MDMA RCTs have enrolled broader anxiety, depression, or PTSD populations — not panic disorder primary.
• Glue 2017 is the most-cited ketamine anxiety RCT but enrolled treatment-resistant GAD/SAD, not panic disorder.
• Important safety caveat: psilocybin and ketamine dosing involve cardiovascular activation, dissociation, and acute anxiety surges that can resemble or trigger panic. Panic patients require especially robust preparation.
• Spravato is NOT approved for panic disorder. MDMA-AT is investigational for PTSD only.

Defining panic disorder (DSM-5)

DSM-5 defines panic disorder by:

1. Recurrent unexpected panic attacks — abrupt surges of intense fear or discomfort peaking within minutes, with ≥4 of 13 symptoms (palpitations, sweating, trembling, shortness of breath, choking, chest pain, nausea, dizziness, chills/heat, paresthesias, derealization/depersonalization, fear of losing control, fear of dying).
2. At least one attack followed by ≥1 month of:
   • Persistent concern or worry about additional attacks or their consequences (losing control, "going crazy", heart attack), and/or
   • Significant maladaptive behaviour change related to the attacks (avoidance of exercise, unfamiliar places, situations associated with prior attacks).
3. Not attributable to substance/medication or another medical condition.
4. Not better explained by another mental disorder (e.g., social anxiety, specific phobia, PTSD, OCD, separation anxiety).

Panic attacks alone are not panic disorder — they occur in many anxiety, mood, and trauma conditions and can be coded as a specifier in DSM-5. Panic disorder requires the recurrent unexpected pattern plus the persistent worry or behavioural change.

Common comorbidities

• Agoraphobia (now a separate DSM-5 diagnosis, though frequently co-occurring): marked fear of ≥2 of public transportation, open spaces, enclosed spaces, lines/crowds, or being outside the home alone.
• Major depressive disorder — co-occurs in roughly half of panic disorder cases.
• Other anxiety disorders — GAD, social anxiety, specific phobia.
• Substance use disorders — particularly alcohol, benzodiazepines, cannabis used to self-manage symptoms.
• PTSD — in patients with trauma history.

For a broader anxiety overview see Anxiety Disorders and Psychedelic-Assisted Therapy. Concurrent panic + substance use is addressed in Concurrent Disorders and Psychedelic-Assisted Therapy.

First-line treatment for panic disorder — foundational

Per CANMAT 2018 anxiety disorder clinical guidelines and consistent with international consensus:

Psychotherapy — panic-specific CBT

Cognitive behavioural therapy designed specifically for panic disorder (the Craske/Barlow Panic Control Treatment protocol and successors) is the most evidence-based psychotherapy for panic disorder. Core components:

• Psychoeducation about the panic cycle and the false-alarm physiology.
• Cognitive restructuring of catastrophic misinterpretations of bodily sensations ("my heart is racing — I'm having a heart attack").
• Interoceptive exposure — deliberate induction of feared bodily sensations (hyperventilation, spinning, breath-holding) to break the conditioned fear response.
• In vivo exposure — graduated re-engagement with avoided situations, particularly when agoraphobic patterns have developed.
• Relapse prevention.

CBT delivered in 10–14 sessions produces large effects sizes in panic disorder RCTs and the published gains are typically durable.

Pharmacotherapy — SSRIs first-line

CANMAT 2018 first-line pharmacotherapy for panic disorder:

• Sertraline, paroxetine, fluoxetine, escitalopram, citalopram — SSRIs
• Venlafaxine XR — SNRI

Practical notes:

• Start low and titrate slowly; panic patients are particularly sensitive to early activation ("jitteriness") in the first 1–2 weeks of SSRI/SNRI initiation, which can resemble panic and lead to treatment dropout.
• Target trial: minimum 8–12 weeks at therapeutic dose before declaring inadequate response.

Benzodiazepines — short-term only

Clonazepam, lorazepam, alprazolam are effective for acute panic but appropriate primarily as short-term or as-needed adjuncts during SSRI initiation, not as monotherapy long-term, given:

• Dependence and tolerance with daily dosing
• Cognitive effects
• Interference with extinction learning during exposure-based CBT (the most actively debated concern — some patients on PRN benzodiazepines complete CBT successfully; others appear to have blunted exposure response).

Combination CBT + SSRI

Combination therapy is reasonable for patients with severe symptoms, prior treatment failure, or significant comorbidity. The CANMAT 2018 guidelines support combining first-line modalities.

What "treatment-resistant panic disorder" looks like

A patient is generally considered to have inadequately responded after:

• ≥2 adequate trials of first-line SSRIs/SNRIs (≥8–12 weeks each at therapeutic dose), and
• An adequate course of panic-specific CBT (or documented inability to access/tolerate CBT).

Next steps per CANMAT 2018 and clinical practice:

• Switch class within SSRIs/SNRIs.
• Augmentation — add a second medication (e.g., low-dose mirtazapine, gabapentin, or short-term benzodiazepine).
• MAOIs (phenelzine) — second/third-line, dietary restrictions, specialist supervision.
• Tricyclic antidepressants (clomipramine, imipramine) — older but effective; tolerability lower than SSRIs.
• Deep TMS — Brainsway H7 coil received FDA clearance for OCD in 2018; expanded indications under continuing study; deep TMS is being evaluated for treatment-resistant anxiety and panic but is not a Canadian first-line option for panic disorder.
• Repeat structured CBT with a different therapist or higher-fidelity protocol.

Psychedelic-assisted therapy is not an established step in this algorithm for panic disorder primary.

The psychedelic evidence base for panic disorder — honest framing

This is the core of why this article matters. The published psychedelic-assisted therapy evidence base for panic disorder as a primary indication is thin compared to TRD, PTSD, or end-of-life distress.

Psilocybin

• The Griffiths 2016 and Ross 2016 J Psychopharmacology trials enrolled patients with cancer-related anxiety and depression — not panic disorder.
• The Goodwin 2022 NEJM COMP001 trial enrolled patients with treatment-resistant depression; comorbid anxiety symptoms improved as a secondary signal but panic disorder primary was not the population.
• The Carhart-Harris 2021 NEJM psilocybin-vs-escitalopram trial enrolled MDD; panic disorder was not the indication.
• We are not aware of an adequately powered RCT of psilocybin in panic disorder primary. The mechanism of action (5-HT2A agonism with broad anxiety effects) is biologically plausible, but plausibility is not RCT evidence.

MDMA

• MDMA-assisted therapy phase 3 evidence (the MAPS Mithoefer/Mitchell program) is in PTSD, not panic disorder. The FDA in August 2024 issued a Complete Response Letter (CRL) for the MDMA-PTSD NDA, requiring an additional phase 3 trial — and that program is for PTSD, not panic.
• Anxiety symptoms in PTSD often include panic features, but MDMA-AT trials were not designed to evaluate panic disorder primary.

Ketamine

• Glue P et al. 2017 (J Psychopharmacol 31(10):1302–1305; PMID 28768444) is the most-cited ketamine RCT in anxiety. Important to read carefully: this study enrolled patients with treatment-resistant generalized anxiety disorder (GAD) and/or social anxiety disorder (SAD) — not panic disorder.
• We are not aware of an adequately powered RCT of ketamine in panic disorder primary. Off-label clinical use occasionally extends to panic, but the evidence is anecdotal and case-series level.

Bottom line

Panic disorder primary is not well-supported by the current published psychedelic-assisted therapy evidence. The strongest signals exist for adjacent conditions — TRD, PTSD, end-of-life anxiety, and broader treatment-resistant GAD/SAD. Patients with panic disorder primary should generally complete first-line trials before considering psychedelic-assisted therapy, and the conversation is more often relevant in the context of panic with comorbid TRD, panic + agoraphobia + PTSD, or panic + concurrent substance use disorder than panic alone.

Safety considerations specific to panic disorder

This is the most clinically important section of this article.

The acute psychedelic dosing experience — whether psilocybin, MDMA, or ketamine — involves features that closely overlap with panic attack symptoms:

• Cardiovascular activation: heart rate and blood pressure increases (psilocybin, MDMA, ketamine).
• Dissociation: derealization and depersonalization (especially ketamine; also psilocybin).
• Surge of anxiety: anticipatory and during onset.
• Bodily sensations: paresthesias, gastrointestinal sensations, temperature shifts.
• Loss of perceived control: a feared theme in panic disorder cognitive structure.

For a panic-disorder patient, these features can trigger an acute panic response during the dosing session, with potential for:

• A traumatic dosing experience that worsens panic-specific cognitions ("my heart races and I can't breathe — I knew this was dangerous").
• Premature termination of the dosing session.
• Reinforcement of the panic-avoidance pattern rather than disruption of it.

Mitigations a responsible clinical program builds in for panic patients:

• Comprehensive screening: panic-specific history, prior treatment trials, current medications, cardiovascular workup, comorbidity screening (psychotic disorder family history is a categorical contraindication for classical psychedelics).
• Substantially extended preparation phase: panic-specific psychoeducation, interoceptive sensitivity work, "cognitive map" of likely body sensations during dosing, explicit framing of cardiovascular activation as expected and not dangerous.
• In-session safety planning: grounding techniques, breathing protocols, the option of ending or pharmacological rescue if needed.
• Therapist familiarity with panic-specific CBT: so that the integration phase reinforces — rather than competes with — interoceptive exposure principles.
• First-line treatments first: for most panic patients, completing a panic-CBT course and adequate SSRI trial before considering investigational psychedelic-assisted therapy is the right ordering.

Comorbid presentations where the conversation is more relevant

The clinical conversation about psychedelic-assisted therapy is more often relevant for:

Panic disorder + treatment-resistant depression

The TRD evidence base supports Spravato (Health Canada approved for TRD May 2020) and off-label ketamine. Panic symptoms may improve as the depression improves, but panic-specific CBT typically still belongs in the care plan.

Panic + agoraphobia + PTSD

PTSD has its own trauma-focused evidence base (prolonged exposure, CPT, EMDR; MDMA-AT investigational). Treating the PTSD often produces secondary improvements in panic features, but the primary indication is the trauma diagnosis. See PTSD and Psychedelic-Assisted Therapy.

Panic + concurrent substance use disorder

Patients self-managing panic with alcohol, benzodiazepines, or cannabis present a concurrent disorder picture. See Concurrent Disorders and Psychedelic-Assisted Therapy.

Panic + obsessive-compulsive features

OCD has its own evidence base (Rodriguez 2013 ketamine RCT, ERP, SSRIs at higher doses). See OCD and Psychedelic-Assisted Therapy — Deep Dive.

Decision framework — panic disorder

Canadian access pathways

Civilian panic disorder

• Public mental health programs offer CBT in most provinces, often with waitlists. Provincial drug plans cover SSRIs/SNRIs subject to formulary rules.
• Private CBT with panic-specialty psychologists/social workers — often the fastest route to high-fidelity panic CBT; costs typically $150–$250/session, sometimes covered by extended health benefits.
• Off-label ketamine for panic disorder is generally not the appropriate first or second step. In treatment-resistant cases with comorbid TRD or anxiety, off-label ketamine clinics evaluate eligibility individually; out-of-pocket dominantly, ~$400–$1,500 per session.
• Spravato for comorbid TRD only — panic disorder is not an approved indication.
• Psilocybin SAP is rarely the right pathway for panic disorder primary; SAP capacity is concentrated in end-of-life distress and TRD.

Veterans (VAC)

• Service-related panic disorder may be compensable; documentation requirements per VAC's mental health policy.
• Psychedelic-assisted therapy: case-by-case for service-related anxiety/PTSD with supporting documentation; panic disorder primary is rarely the indication.

Workers' compensation

• WSIB (Ontario), WCB (Alberta) and provincial counterparts: panic disorder may be compensable depending on workplace exposure and provincial framework. Standard treatment typically follows first-line CBT/SSRI before any consideration of investigational pathways.

For full pathway and cost detail see Insurance Coverage for Psychedelic-Assisted Therapy in Canada.

How ATMA CENA works with panic disorder patients

• Comprehensive intake: panic disorder history, prior treatments (CBT, SSRI/SNRI, benzodiazepine), agoraphobic patterns, comorbid depression/PTSD/SUD screening, cardiovascular review, family history of psychotic illness.
• Routing to first-line care: where panic-CBT and SSRI trials have not yet been completed, ATMA CENA will route to or coordinate with first-line evidence-based providers before considering psychedelic-assisted pathways.
• Three-phase model with extended preparation for eligible patients: preparation explicitly addresses the overlap between dosing-experience features and panic-attack features.
• Coordinated care: panic-specialty CBT therapist remains the primary therapist throughout.
• Honest framing: no outcome promises; psychedelic-assisted therapy is investigational adjunct, not a replacement for first-line panic disorder treatment.

Frequently asked questions

Is any psychedelic-assisted therapy approved for panic disorder in Canada? No. No psychedelic-assisted therapy is Health Canada-approved for panic disorder. Spravato is approved for TRD only. Off-label ketamine and psilocybin SAP are investigational and not panic-indicated.

What's the strongest evidence for psychedelic-assisted therapy in panic disorder specifically? Honestly: there isn't strong panic-disorder-primary published evidence. The most-cited ketamine anxiety RCT (Glue 2017) enrolled GAD/SAD, not panic disorder. Psilocybin and MDMA RCTs have enrolled adjacent populations.

Should I try CBT and SSRIs before exploring psychedelic options? Generally yes. Panic-specific CBT (Craske/Barlow protocols) and SSRIs (sertraline, paroxetine, fluoxetine, escitalopram) or SNRIs (venlafaxine) are first-line per CANMAT 2018 and well-supported by RCT evidence. Psychedelic-assisted therapy is appropriate to consider after first-line trials have not produced adequate response — and even then the panic-disorder-primary evidence base is thin.

Can a psychedelic experience trigger a panic attack? Yes — this is a real concern. Psilocybin, MDMA, and ketamine dosing involve cardiovascular activation, dissociation, and acute anxiety surges that can resemble or trigger panic in panic-disorder patients. Substantial preparation, comprehensive screening, and panic-specific psychoeducation are essential mitigations. For some patients, the risk-benefit calculus argues against the dosing pathway.

What about benzodiazepines like clonazepam or lorazepam? Benzodiazepines are effective for acute panic but appropriate primarily for short-term use or PRN during SSRI initiation, not as long-term monotherapy. Dependence, tolerance, and possible interference with exposure-based CBT are the concerns.

What if I have panic disorder plus treatment-resistant depression? This is a more common scenario for the psychedelic-assisted therapy conversation. Spravato (Health Canada approved for TRD) and off-label ketamine address the depression; panic-specific CBT typically still belongs in the care plan. See Treatment-Resistant Depression and Psychedelic-Assisted Therapy.

What about deep TMS for panic disorder? Deep TMS (Brainsway) has FDA clearance for OCD; investigation is ongoing for treatment-resistant anxiety and panic. It is not a first-line Canadian option for panic disorder but is a meaningful option in the "what comes after first-line" discussion.

Does Glue 2017 mean ketamine works for panic disorder? Glue 2017 enrolled treatment-resistant GAD and SAD, not panic disorder. Generalization to panic disorder primary is not directly supported by the Glue trial.

What's the cost of treatment for panic disorder in Canada?

• First-line CBT: $150–$250/session privately; often covered by extended health benefits; publicly funded options available with waitlists.
• First-line SSRIs/SNRIs: typically covered by provincial drug plans subject to formulary.
• Off-label ketamine (treatment-resistant cases, often comorbid): ~$400–$1,500/session; generally not insurance-covered.
• Psilocybin SAP: variable; rarely the right indication for panic primary.

What's "agoraphobia" and how does it relate to panic disorder? Agoraphobia (DSM-5, separate diagnosis) is fear of two or more situations involving difficulty escape (public transport, open or enclosed spaces, crowds, being alone outside the home). It frequently co-occurs with panic disorder; in vivo exposure within panic-CBT is a core treatment component.

Sources

1. American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Panic disorder criteria. Arlington, VA.
2. Katzman MA, Bleau P, Blier P, et al. (2014). Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry, 14(Suppl 1):S1. PMID: 25081580.
3. Craske MG, Barlow DH. (2007). Mastery of Your Anxiety and Panic: Workbook (4th ed.). Oxford University Press. Panic Control Treatment protocol.
4. Glue P, Medlicott NJ, Harland S, et al. (2017). Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. J Psychopharmacol, 31(10):1302-1305. PMID: 28768444. Population enrolled: treatment-resistant GAD/SAD — not panic disorder.
5. Rodriguez CI, Kegeles LS, Levinson A, et al. (2013). Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology, 38(12):2475-83. PMID: 23631729.
6. Griffiths RR, Johnson MW, Carducci MA, et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. J Psychopharmacol, 30(12):1181-1197.
7. Ross S, Bossis A, Guss J, et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer. J Psychopharmacol, 30(12):1165-1180.
8. Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. NEJM, 387(18):1637-1648. PMID: 36322843.
9. Carhart-Harris R, Giribaldi B, Watts R, et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. NEJM, 384(15):1402-1411. PMID: 33852780.
10. Health Canada — Special Access Program for psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
11. Health Canada — Spravato (esketamine) Product Monograph: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
12. Public Health Agency of Canada — Mental Illness Surveillance: https://health-infobase.canada.ca/mental-illness/

Related articles

• Anxiety Disorders and Psychedelic-Assisted Therapy — parent overview
• OCD and Psychedelic-Assisted Therapy — Deep Dive
• PTSD and Psychedelic-Assisted Therapy
• Treatment-Resistant Depression and Psychedelic-Assisted Therapy
• Concurrent Disorders and Psychedelic-Assisted Therapy
• Ketamine Therapy in Canada
• Psilocybin Therapy in Canada

Last updated: 2026-05-06